Market Size –
The drug eluting stent market size has grown strongly in recent years. It will grow from $7.05 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the need for improved treatment options, clinical evidence, regulatory approval, healthcare economics, and guidelines and recommendations.
The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $10.52 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to an aging population and chronic disease burden, the expansion of indications, healthcare reimbursement policies, global market expansion, and patient-centered care. Major trends in the forecast period include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report
Scope Of Drug Eluting Stent Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Drug Eluting Stent Market Overview
Market Drivers –
The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the percentage of coronary heart disease in adults aged 18 and over in 2020 was 4.6%, which increased to 4.9% in 2022. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.
Market Trends –
Companies operating in the drug-eluting stent market are focusing on developing innovative delivery systems, such as the dual-layer balloon, to improve patient outcomes and advance the field of interventional cardiology. A dual-layer balloon in a drug-eluting stent system enhances precision in drug delivery and stent deployment by providing better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc, an Ireland-based provider of medical supplies, launched Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems that build upon the acute performance and clinical data from the previous generation of Resolute Onyx DES. The Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx, with a broad size matrix to treat patients ranging from 2.0mm to 5.0mm in diameter. The Onyx Frontier DES incorporates notable design enhancements, such as a groundbreaking dual-layer balloon, reduced crossing profile, and improved catheter flexibility. These improvements yield a 16% increase in deliverability over the prior Resolute Onyx DES generation, all while preserving radial strength.
The drug eluting stent market covered in this report is segmented –
1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
4) By End-User: Hospitals, Specialty Clinics
Get an inside scoop of the drug eluting stent market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp
Regional Insights –
North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.
Table of Contents
1. Executive Summary
2. Drug Eluting Stent Market Characteristics
3. Drug Eluting Stent Market Trends And Strategies
4. Drug Eluting Stent Market – Macro Economic Scenario
5. Global Drug Eluting Stent Market Size and Growth
.
.
.
31. Drug Eluting Stent Market Other Major And Innovative Companies
32. Global Drug Eluting Stent Market Competitive Benchmarking
33. Global Drug Eluting Stent Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Drug Eluting Stent Market
35. Drug Eluting Stent Market Future Outlook and Potential Analysis
36.Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
